Actively Recruiting
Asian Myeloproliferative Neoplasm (MPN) Registry
Led by The University of Hong Kong · Updated on 2023-05-31
1000
Participants Needed
1
Research Sites
187 weeks
Total Duration
On this page
Sponsors
T
The University of Hong Kong
Lead Sponsor
N
Novartis
Collaborating Sponsor
AI-Summary
What this Trial Is About
This is a multinational, multicenter, prospective and retrospective, observational, cohort study of patients with myeloproliferative neoplasm.
CONDITIONS
Official Title
Asian Myeloproliferative Neoplasm (MPN) Registry
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older at the time of MPN diagnosis
- Diagnosed with one of the following according to 2017 WHO classification or re-evaluated accordingly: polycythemia vera, essential thrombocythemia, primary myelofibrosis (pre-fibrotic or fibrotic stage), post-polycythemia vera myelofibrosis, post-essential thrombocythemia myelofibrosis, or MPN-unclassifiable
- Able to provide informed consent
You will not qualify if you...
- Diagnosed with myelodysplastic syndrome, myelodysplastic syndrome/myeloproliferative neoplasm overlap, or chronic myeloid leukemia BCR-ABL1 positive as defined by 2017 WHO classification
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Department of Medicine, Queen Mary Hospital
Hong Kong, Hong Kong
Actively Recruiting
Research Team
H
Harinder Gill, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here